Bristol-Myers Squibb Company has announced the commercial launch of the ORENCIA ClickJectTM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis (RA). The ORENCIA ClickJect delivers 125 mg of subcutaneous (SC)ORENCIA with push button operation and injection confirmation, which may reduce the possibility of user errors. TheORENCIA ClickJect has an ergonomic design and non-slip grip that may allow for control by dexterity-compromised patients. ORENCIA is the only RA biologic that offers three administration options: IV infusion, prefilled syringe and Autoinjector.1- ORENCIA is a prescription medicine indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ORENCIA should not be administered concomitantly with tumor necrosis factor (TNF) antagonists, and is not recommended for use concomitantly with other biologic RA therapy, such as anakinra.
“Today’s launch of the ORENCIA ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector,” said Chris Boerner, Head of U.S. Commercial, Bristol-Myers Squibb. “This approval offers more options for healthcare providers and members of the arthritis community to consider when selecting the optimal treatment and administration option for each individual.”